AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05209438 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cereset Research
Description: Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
Study NCT05209438 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cereset Research
Description: Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
Study NCT04899921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous injection
Study NCT05040152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counseling and Surveillance
Description: Receive dietary recommendations
Study NCT05040152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete home exercises
Study NCT04899921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenously (IV) into the vein
Study NCT06162546 — intervention group
Intervention type: OTHER
Intervention: Registry
Description: Registry Participation, providing data and clinical specimen
Study NCT06195969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: automated instant message-guided hypertension management intervention group
Description: Participants in intervention group will receive the EMI for 4 weeks. Based on the steps of mobile message development recommended by Abroms, et al., we will develop a message content library and protocol for EMI delivery
Study NCT04899921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troriluzole
Description: Taken orally
Study NCT05040152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive education brochures
Study NCT05040152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04899921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Taken orally
Study NCT05682287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 448kHz capacitive resistive monopolar radiofrequency
Description: Capacitive resistive monopolar radiofrequency (CRM) treatment is a type of medical procedure that uses radiofrequency energy to heat the targeted tissue.
Study NCT05682287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proprioceptive Neuromuscular Facilitation
Description: Proprioceptive neuromuscular facilitation (PNF) is a type of physical therapy that uses techniques such as stretching and strengthening exercises to improve muscle function and movement patterns.
Study NCT05682287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: Proprioceptive neuromuscular facilitation (PNF) is a type of physical therapy that uses techniques such as stretching and strengthening exercises to improve muscle function and movement patterns.
Study NCT05426031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protamine fixed dose
Description: 250 mg of protamine intravenously (IV), one time use
Study NCT05426031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protamine ratio dose
Description: 1mg of protamine per 100 units of heparin given intravenously (IV), one time use
Study NCT05122260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q-Griffithsin
Description: intranasal spray administered as a single dose
Study NCT05122260 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intranasal spray administered as a single dose
Study NCT05709067 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 6 Billion CFU per day
Study NCT05709067 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 CFU per day
Study NCT04895293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBM-007 Injectable Solution
Description: Sterile solution
Study NCT05946291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure injury training
Description: Pressure injury training with mulage application on a standardized patient
Study NCT05946291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulated Manneqquin training
Description: Pressure injury training with mulage application on a simulated manneqquin
Study NCT04739618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keytruda Injectable Product
Description: PD-1 inhibitor antibody
Study NCT04739618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yervoy Injectable Product
Description: Anti-CTLA-4 antibody
Study NCT04739618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 1 mL injected into each non-ablative cryosurgical freezing zone. Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days after each treatment.
Study NCT04739618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-ablative Cryosurgical freezing
Description: To induce immediate necrosis and necroptosis and a rim of injured cancer cells, thereby exposing a complete range of patient-specific tumor antigens that are specific to the treated subject.
Study NCT06126952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)
Description: 2 sprays per nostril of Azelastine 0.15% twice daily.~Total dose of active drug:~1644 mcg azelastine hydrochloride per day
Study NCT06126952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray
Description: 2 sprays per nostril of Placebo twice daily.
Study NCT05040152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05040152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive telephone-based weight loss intervention
Study NCT06415994 — intervention group
Intervention type: DRUG
Intervention: Buprenorphine or Methadone Treatment
Description: Pregnant mothers must be taking Buprenorphine or Methadone
Study NCT06126952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray
Description: 2 sprays per nostril of Ryaltris twice daily.~Total dose of active drug:~200 mcg mometasone furoate and 4800 mcg olopatadine per day
Study NCT00881998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Total Hip Arthroplasty
Study NCT00881998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Total Hip Arthroplasty
Study NCT05008575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD33 CAR NK cells
Description: 6×10\^8, 12×10\^8, 18×10\^8/KG Treatment follows a lymphodepletion
Study NCT05008575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
Study NCT05008575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
Study NCT06323278 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive training
Description: The training, provided by normal clinical practice, will consist of two cycles of cognitive stimulation (8 sessions each) structured and aimed at maintaining and learning compensatory strategies that take advantage of the integrated cognitive skills.
Study NCT04856774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701；BP102
Description: Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion~Phase Ib: SHR-1701 30mg/kg + BP102 15mg/kg Q3w as starting dose, until recommended phase 2 dose is determined.
Study NCT04501614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib tablets.
Study NCT04501614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Agents
Description: Chemotherapy agents for reinduction include vincristine, dexamethasone, polyethylene glycol (PEG)-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), daunorubicin. Agents for intrathecal (IT) chemotherapy, central nervous system (CNS)-1/2: IT methotrexate chemotherapy, or CNS-3: triple intrathecal (ITT) methotrexate, hydrocortisone, cytarabine. Chemotherapy agents for consolidation include dexamethasone, vincristine, methotrexate, PEG-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), cyclophosphamide, etoposide, CNS-1/2: IT methotrexate chemotherapy, CNS-3: ITT chemotherapy methotrexate, hydrocortisone, cytarabine. The doses for chemotherapy agents for reinduction will be given as per standard of care.
Study NCT06179303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study NCT06179303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO
Study NCT06179303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06179303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT06179303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo clinical imaging for tumor assessment
Study NCT06179303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO
Study NCT06179303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV
Study NCT06179303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Fluoro Furanyl Norprogesterone
Description: Given IV
Study NCT06179303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM injection
Study NCT06179303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing Hormone Analog
Description: Given GnRH analog
Study NCT06179303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT06179303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06179303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given PO
Study NCT06179303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Estradiol
Description: Given PO
Study NCT06426329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Therapeutic touch, as meaningful touch, is included in complementary medicine in the literature. It provides physical, emotional and spiritual relief, improves physiological health, makes the person feel valuable, gives confidence, peace, calmness and increases self-confidence.
Study NCT04851873 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OAV101
Description: Gene Therapy - 1.1e14 vector genome (vg)/kg as a one-time IV infusion was administered over approximately 60 minutes.
Study NCT06415994 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal and Placental MRI
Description: Two MRIs :~* Second Trimester~* Third Trimester
Study NCT06415994 — intervention group
Intervention type: BEHAVIORAL
Intervention: Child Developmental Assessment
Description: At 1 year of life child will receive a developmental assessment
Study NCT06415994 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants will answer questionnaires on their medical history, pregnancy, substance use, and after birth: their child's development
Study NCT06001918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nectero EAST System
Description: Treated subjects will undergo an endovascular procedure with the Nectero EAST system and receive the Stabilizer Infusion Solution (drug) within 30 days of the study eligibility by CT scan as a one-time local delivery of the drug.
Study NCT06101303 — intervention group
Intervention type: OTHER
Intervention: Psychophysical assessment
Description: Thermal stimuli: The Thermal Sensory Analyzer will be used to deliver heat and cold stimuli. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water bath or an electronic electronic temperature-controlled water bath. Participants will be free to pull out of the water bath at any time.~Pressure stimuli: Pressure stimuli will be applied by using a handheld algometer. These devices have a round probe that allows quantifying the amount of pressure that is being applied by real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.~Mechanical stimuli: A set of standardised von Frey filaments (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 and 256mN). The contact area of the hairs with the skin is of uniform size (\<1 mm²) and texture.
Study NCT06101303 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychophysical assessments of experimental pain
Description: Pain ratings- Pain intensity and pain unpleasantness ratings will be assessed~Pain thresholds to heat, cold and/or pressure will be tested and participants will be instructed to press a button the first moment they feel pain.~Temporal summation- participants will rate the pain evoked by a single pinprick stimulus and by a series of 10 identical pinprick stimuli.~Conditioned pain modulation (CPM) efficiency - CPM testing includes the application of a test stimulus without conditioning (heat or pressure stimuli) and a subsequent application of the same test stimulus together with a conditioning stimulus (cold stimulus).~Offset analgesia will be assessed using the three-temperature method (T1°C 5s, T1+1°C 5s, T1°C 20s). During the OA paradigm, real time pain intensity ratings will be obtained~Cold pain tolerance will be assessed by having participants immerse their hand or foot in a cold water bath. Tolerance will be defined by the time of hand/foot withdrawal.
Study NCT06101303 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood, urine and saliva samples
Description: Blood (approximately 2 tablespoons), urine and saliva samples will be collected and sent to ZRT Laboratory, LabCorp, or internal Washington University lab for analyses of sex hormone levels (e.g., testosterone, estradiol, progesterone). Additional samples will be stored in a biobank for future processing.
Study NCT06101303 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy and surgery-related data.
Description: During the surgery, biopsies will be collected from the endometriosis lesions as well as from a healthy peritoneum. If there are no endometriosis lesions, biopsies will be taken of two common locations where endometriosis lesion grows (the infra-ovarian fossa). The lesions will be characterized based on their appearance and invasiveness of the lesions (i.e., powder-burn lesions, nonclassical red or white lesions, and superficially or deeply infiltrating (>5mm) lesions). In addition, surgery-related data such as the incision size, type of anesthesia, pain ratings after the surgery, analgesic medication after the surgery, and side effects will be documented. Blood, saliva, urine, and samples will be collected for hormonal analyses or stored in a Biobank for future analyses.
Study NCT06584929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm CQ nicotine patch
Description: Two week supply provided to participants on study.
Study NCT06584929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette Nicotine Lozenges
Description: Two week supply provided to participants on study.
Study NCT06427707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Infusion of propofol, lidocaine, Magnesium sulfate
Description: intravenous infusion of propofol 6-10 mg.kg-1.h-1, lidocaine (lidocaine 2% 400mg in 20 ml) bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1. the effect of either Propofol injection, or ketamine injection or dexmeditomidine injection on intraoperative bleeding
Study NCT06427707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous infusion of ketamine, lidocaine, Magnesium sulfate
Description: Patients will receive intravenous infusion of Ketamine 0.1-0.2 mg.kg-1.h-1 (intravenous infusion of propofol 6-10 mg.kg-1.h-1, lidocaine (lidocaine 2% 400mg in 20 ml) bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1. dose of 1 mg.kg-1), lidocaine bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1.
Study NCT06427707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous infusion of dexmedetomidine, lidocaine, Magnesium sulfate
Description: Dexmeditomidine (Precedex® 200 mcg.2ml-1) with a rate of 0.2-0.6 mcg.Kg-1.h-1. lidocaine bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1
Study NCT04611529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: Ibuprofen 400mg
Study NCT04611529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: Ibuprofen 400mg
Study NCT04611529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical diclofenac
Description: Diclofenac 1% gel 4gm
Study NCT04611529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical diclofenac
Description: Diclofenac 1% gel 4gm
Study NCT06175988 — intervention group
Intervention type: OTHER
Intervention: Visceral adiposity
Description: Visceral adiposity assess by the visceral adiposity index
Study NCT05470023 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OTC Toothpastes or Mouthrinses
Description: OTC Toothpastes or mouthrinses used according to standard of care
Study NCT05679908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-1900
Description: Patients will spray TNX-1900 once into each nostril.
Study NCT05679908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: Patients will spray placebo nasal spray once into each nostril.
Study NCT05679908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nasal Spray
Description: Patients will spray placebo nasal spray once into each nostril.
Study NCT05205733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mail-in semen analysis kit
Description: Presumably an easier, convenient, and more comfortable way to provide a semen analysis with an in-home mail-in semen analysis kit
Study NCT05397756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: observer tool
Description: The observer tool used will be the Anaesthetist Non-Technical Skills (ANTS) tool previously published by Fletcher et al. and translated in French. The ANTS scoring system uses four categories assessing task management, teamworking, situation awareness and decision-making. The observers will use an observer tool it when they will be not role role-playing
Study NCT06327451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: Liptor is a capsule in the form of 20 mg, once daily.
Study NCT05945914 — intervention group
Intervention type: PROCEDURE
Intervention: Oncoplastic Entirely Robot-Assisted Approach (OPERA)
Description: Robotic-assisted surgery in both mastectomy and free DIEP flap harvest, so-called Oncoplastic Entirely Robot-Assisted Approach (OPERA).
Study NCT05759650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Execution of different motor tasks typical of daily life and work
Description: Patients with obesity will carry out different motor tasks typical of daily life and work and, using optoelectronic systems based on passive markers, force platforms and electromyographic systems, kinematic and kinetic parameters of movement will be recorded and analysed for the implementation of an integrated protocol for the clinical evaluation of subjects with obesity.